Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease

Li Zhou; Shanglong Feng; Guangyu Sun; Baolin Tang; Xiaoyu Zhu; Kaidi Song; Xuhan Zhang; Huaiwei Lu; Huilan Liu; Zimin Sun; Changcheng Zheng

doi:10.2147/IDR.S191462

Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease

Infect Drug Resist. 2019 Feb 26:12:481-491. doi: 10.2147/IDR.S191462. eCollection 2019.

Authors

Li Zhou¹, Shanglong Feng^{1

2}, Guangyu Sun¹, Baolin Tang¹, Xiaoyu Zhu¹, Kaidi Song¹, Xuhan Zhang¹, Huaiwei Lu³, Huilan Liu¹, Zimin Sun¹, Changcheng Zheng^{1

2}

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, zhengchch1123@ustc.edu.cn.
² Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China, zhengchch1123@ustc.edu.cn.
³ Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Abstract

Background: Extensively drug-resistant Gram-negative bacterial (XDR-GNB) bloodstream infection (BSI) is difficult to treat and is associated with a high mortality rate in patients with hematological diseases. The aim of this study is to investigate the predisposing risk factors and the efficacy of the antibiotic treatment in these patients, including exploration of efficacy and adverse effects of high-dose tigecycline.

Methods: Between January 2013 and December 2017, 27 XDR-GNB BSI patients with hematological diseases were diagnosed and retrospectively reviewed in the current study.

Results: Clinical response in patients with severe complications (such as severe neutropenia >10 days, grade III-IV acute graft-versus-host disease (aGVHD), and concurrent pneumonia) was significantly lower than in patients without or with only mild complications (P=0.033). The efficacy rate was 62.5% (10/16) in patients with tigecycline-based combination therapy regimen, 77.8% (7/9) with a high-dose tigecycline regimen, and 42.9% (3/7) with a standard-dose tigecycline regimen (P=0.36). The 30-day survival rates of patients undergoing high-dose or standard-dose tigecycline treatment were 66.7% (95% CI: 28.2-87.8) and 57.1% (95% CI: 17.2-83.7), respectively, (P=0.603). Patients with mild complications were associated with superior 30-day survival rates than patients with severe complications (93.8% vs 36.4%, P=0.001), >10 days of neutropenia (90.9% vs 33.3%, P=0.012), severe aGVHD (100% vs 40%, P=0.049), and concurrent pneumonia (84.6% vs 57.1%, P=0.048).

Conclusion: Our study indicated that XDR-GNB BSI in patients of hematological diseases with severe complications, such as long duration of neutropenia (>10 days) and severe aGVHD were associated with poor clinical response and short survival. We first indicated that these patients undergoing high-dose tigecycline treatment had an improved clinical response and an increased 30-day survival rate compared with the standard-dose group, although the differences were not statistically significant. This might be due to more severe complicated patients enrolled in high-dose group and the limited number size in our study.

Keywords: bloodstream infection; carbapenem resistant bacterial infection; hematological malignancies; high-dose tigecycline.